查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1513318

疫苗市场：按技术类型、按适应症、按最终用户：2024-2035 年全球机会分析和产业预测

Vaccines Market By Technology Type, By Indication, By End User : Global Opportunity Analysis and Industry Forecast, 2024-2035
出版日期: | 出版商: Allied Market Research | 英文 350 Pages | 商品交期: 2-3个工作天内

价格
2023年疫苗市值为432亿美元，预计2035年将达到907亿美元，2024年至2035年的复合年增长率为6.4%。疫苗是一种提供针对特定感染疾病的免疫力的生物製药。疫苗通常含有减毒或惰性的病原体、其毒素和表面蛋白，以刺激免疫系统识别和记住病原体。当您接种疫苗时，您的免疫系统会透过产生抗体并激活特异性病原体的免疫细胞来做出反应。这在体内建立了一种防御机制，如果以后暴露于实际的感染疾病，免疫系统可以快速识别并消灭病原体，预防或减轻疾病的严重程度。历史上，疫苗帮助控制和消除了许多致命疾病，使其成为现代医学最重要的进步之一。
疫苗市场-IMG1
疫苗市场的成长主要是由需要疫苗接种的疾病盛行率上升所推动的，例如流感、肺炎球菌疾病、HPV和其他感染疾病。例如，美国疾病管制与预防美国(CDC) 估计 2023 年将有 3,100 万人感染流感。此外，政府对疫苗研发、生产基础设施和公共免疫计画的投资对疫苗市场也有重大影响。官民合作关係津贴、补贴、税收优惠和法律规范奖励疫苗开发并确保安全性、有效性和品质标准。美国食品药物管理局(FDA)、欧洲药品管理局 (EMA) 和世界卫生组织 (WHO) 等监管机构在评估和授权疫苗、影响市场准入和采用方面发挥着至关重要的作用。然而，高昂的开发成本、复杂的製造流程和严格的监管要求导致疫苗价格高昂，而负担能力有限，特别是在低收入和中等收入国家（LMIC），导致市场可能抑製成长。相较之下，生物技术、基因组学和免疫学的进步为透过开发新的和改进的疫苗来扩大疾病预防和控制提供了机会。新出现的感染疾病、抗菌素抗药性和重新出现的病原体凸显了对创新疫苗解决方案的需求，以解决未满足的医疗需求并减少公共卫生威胁。疫苗市场按技术类型、适应症、最终用户和地区进行细分。依技术类型，疫苗分为重组/结合疫苗、减毒活病毒疫苗、灭活疫苗、类毒素疫苗等。依适应症，肺炎链球菌感染、流感、人类乳突病毒、脑膜炎双球菌病菌感染、轮状病毒、德国麻疹、麻疹/腮腺炎/德国麻疹、白喉/百日咳/破伤风（DTP）、脊髓灰质炎、肝炎等被归类为适应症。按最终用户划分，市场分为儿童、成人和旅行者。按地区划分，我们有北美（美国、加拿大、墨西哥）、欧洲（德国、法国、英国、义大利、西班牙其他欧洲国家地区）、亚太地区（日本、中国、澳洲、印度、韩国、及其他亚太地区），以南美地区（巴西、沙乌地阿拉伯、非洲和其他南美地区）为分析对象。全球疫苗市场的主要主要企业有默克公司、辉瑞公司、赛诺菲公司、印度血清研究所、Bavarian Nordic、CSL Limited、Emergent Bio Solutions Inc.、葛兰素史克公司、智飞生物公司。特生物技术公司。市场上的主要企业已将临床试验、产品上市、产品核可和业务扩张作为扩大产品系列的关键策略。

相关人员的主要利益

  • 本报告对2023年至2035年疫苗市场分析的细分市场、当前趋势、估计/趋势和动态进行了定量分析，以揭示疫苗市场的当前机会。
  • 我们提供市场研究以及与市场驱动因素、市场限制和市场机会相关的资讯。
  • 波特的五力分析强调买家和供应商帮助相关人员做出利润驱动的商业决策并加强供应商-买家网路的潜力。
  • 对疫苗市场区隔的详细分析有助于识别市场机会。
  • 每个地区的主要国家都根据其对全球市场的收益贡献绘製了地图。
  • 市场参与者定位有助于基准化分析，并提供对市场参与者当前位置的清晰了解。
  • 该报告包括对区域和全球疫苗市场趋势、主要企业、细分市场、应用领域和市场成长策略的分析。其他好处包括：
  • 季度更新和*（仅适用于企业许可证）
  • 在购买之前或之后免费更新您选择的 5 个额外公司简介。
  • 购买 5 个用户和企业用户授权即可免费获得下一个版本。
  • 16 小时分析师支援*（购买后，如果您的报表审查发现额外的资料需求，您将获得 16 小时分析师支持，以解决任何问题或售后查询）
  • 15% 免费自订*（如果报告的范围或细分不符合您的要求，15% 相当于 3 个工作日的免费工作。）
  • 5 个用户许可证和企业用户许可证的免费资料包。 （Excel版报告）
  • 如果您的报告超过 6-12 个月，我们将免费提供更新的报告。
  • 24 小时优先回应*。
  • 免费取得最新的行业资讯和白皮书。
  • 监管指引
  • 根据客户兴趣新增其他公司简介
  • 按国家或地区进行的附加分析 – 市场规模和预测
  • 公司简介的扩充列表
  • 历史市场资料
  • 主要参与者的详细资料（Excel格式，包括位置、联络资讯、供应商/供应商网路等）

目录

第一章简介

第 2 章执行摘要

第三章市场概况

  • 市场定义和范围
  • 主要发现
    • 影响因素
    • 主要投资机会
  • 波特五力分析
  • 市场动态
    • 促进因素
    • 抑制因素
    • 机会

第四章疫苗市场：依技术类型

  • 概述
  • 重组疫苗和结合疫苗
  • 活病毒疫苗
  • 灭活疫苗
  • 类毒素疫苗
  • 其他的

第五章 疫苗市场：依适应症分类

  • 概述
  • 肺炎链球菌感染
  • 流感
  • 人类乳突病毒
  • 病菌感染
  • 轮状病毒
  • 水痘
  • 麻疹、腮腺炎、德国麻疹
  • 白喉、百日咳和破伤风 (DTP)
  • 脊髓灰质炎
  • 肝炎
  • 其他适应症

第六章 疫苗市场：依最终使用者分类

  • 概述
  • 小儿科
  • 成人
  • 游客

第七章 疫苗市场：依地区

  • 概述
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 其他的
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 韩国
    • 其他的
  • 拉丁美洲/中东/非洲
    • 巴西
    • 沙乌地阿拉伯
    • 南非
    • 其他的

第八章 竞争格局

  • 介绍
  • 关键成功策略
  • 10家主要企业产品图谱
  • 竞争对手仪表板
  • 竞争热图
  • 2023年主要企业定位

第九章 公司简介

  • CSL Limited
  • Emergent Bio Solutions Inc.
  • GlaxoSmithKline Plc.
  • Merck & Co., Inc.
  • Pfizer
  • Sanofi
  • Serum Institute of India Pvt. Ltd.
  • Bavarian Nordic
  • Zhi Fei Biological
  • Bharat Biotech
Product Code: A00168
The vaccine market was valued at $43.2 billion in 2023 and is projected to reach $90.7 billion by 2035, registering a CAGR of 6.4% from 2024 to 2035. A vaccine is a biological preparation that provides immunity to a particular infectious disease. It typically contains weakened or inactive forms of the pathogen, its toxins, or surface proteins, which stimulate the immune system to recognize and remember the pathogen. When people are vaccinated, their immune system responds by producing antibodies and activating immune cells specific to that pathogen. This creates a defense mechanism within the body, so if a person is later exposed to the actual infectious agent, the immune system can quickly recognize and destroy it, preventing or reducing the severity of the disease. Vaccines have been instrumental in controlling and eradicating many deadly diseases throughout history, making them one of the most significant advancements in modern medicine.
Vaccines Market - IMG1
The growth of the vaccine market is primarily driven by rise in prevalence of diseases, such as influenza, pneumococcal disease, HPV, and other infections, requiring administration of vaccines. For instance, in 2023, Centers for Disease Control and Prevention (CDC) estimated that 31 million people were sick with flu. In addition, government investment in vaccine research and development, manufacturing infrastructure, and public immunization programs significantly impacts the vaccine market. Public-private partnerships, grants, tax incentives, and regulatory frameworks incentivize vaccine development and ensure safety, efficacy, and quality standards. Regulatory agencies, such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and the World Health Organization (WHO), play pivotal roles in evaluating and approving vaccines for licensure, which influences market access and adoption. However, the high development costs, complex manufacturing processes, and stringent regulatory requirements contribute to the high prices of vaccines, limiting affordability, especially in low- and middle-income countries (LMICs) which may restrain the market growth. In contrast, due to ongoing advancements in biotechnology, genomics, and immunology, there is an opportunity to expand disease prevention and control through the development of new and improved vaccines. Emerging infectious diseases, antimicrobial resistance, and re-emerging pathogens underscore the need for innovative vaccine solutions to address unmet medical needs and mitigate public health threats. The vaccine market is segmented on the basis of technology type, indication, end user, and region. By technology type, the market is categorized into recombinant and conjugate vaccines, live attenuated vaccines, inactivated vaccines, toxoid vaccines, and others. As per indication, the market is divided into pneumococcal disease, influenza, human papilloma virus, meningococcal disease, rotavirus, varicella, measles, mumps, and rubella, diphtheria, pertussis, and tetanus (DTP), polio, hepatitis, and other indications. Depending on end user, the market is categorized into pediatric, adults, and travelers. Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, South Africa, and rest of LAMEA). Major key players that operate in the global vaccine market are Merck & Co., Inc., Pfizer, Sanofi, Serum Institute of India Pvt. Ltd., Bavarian Nordic, CSL Limited, Emergent Bio Solutions Inc., GlaxoSmithKline plc., Zhi Fei Biological, and Bharat Biotech. The key players operating in the market have adopted clinical trial, product launch, product approval, and expansion as their key strategies to expand their product portfolio.

Key Benefits for Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the vaccines market analysis from 2023 to 2035 to identify the prevailing vaccines market opportunities.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the vaccines market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global vaccines market trends, key players, market segments, application areas, and market growth strategies. Additional benefits you will get with this purchase are:
  • Quarterly Update and* (only available with a corporate license, on listed price)
  • 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
  • Free Upcoming Version on the Purchase of Five and Enterprise User License.
  • 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
  • 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
  • Free data Pack on the Five and Enterprise User License. (Excel version of the report)
  • Free Updated report if the report is 6-12 months old or older.
  • 24-hour priority response*
  • Free Industry updates and white papers. Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)
  • Regulatory Guidelines
  • Additional company profiles with specific to client's interest
  • Additional country or region analysis- market size and forecast
  • Expanded list for Company Profiles
  • Historic market data
  • Key player details (including location, contact details, supplier/vendor network etc. in excel format)

Key Market Segments

By Technology Type

  • Inactivated Vaccines
  • Toxoid Vaccines
  • Others
  • Recombinant and Conjugate Vaccines
  • Live Attenuated Vaccines

By Indication

  • Pneumococcal Disease
  • Influenza
  • Human Papilloma Virus
  • Meningococcal Disease
  • Rotavirus
  • Varicella
  • Measles, Mumps, and Rubella
  • Diphtheria, Pertussis, and Tetanus (DTP)
  • Polio
  • Hepatitis
  • Other Indications

By End User

  • Pediatric
  • Adults
  • Travelers

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA

Key Market Players:

    • CSL Limited
    • Emergent Bi

Solutions Inc.

    • GlaxoSmithKline Plc.
    • Merck & Co., Inc.
    • Pfizer
    • Sanofi
    • Serum Institute of India Pvt. Ltd.
    • Bavarian Nordic
    • Zhi Fei Biological
    • Bharat Biotech

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

  • 1.1. Report description
  • 1.2. Key market segments
  • 1.3. Key benefits to the stakeholders
  • 1.4. Research methodology
    • 1.4.1. Primary research
    • 1.4.2. Secondary research
    • 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO perspective

CHAPTER 3: MARKET OVERVIEW

  • 3.1. Market definition and scope
  • 3.2. Key findings
    • 3.2.1. Top impacting factors
    • 3.2.2. Top investment pockets
  • 3.3. Porter's five forces analysis
  • 3.4. Market dynamics
    • 3.4.1. Drivers
    • 3.4.2. Restraints
    • 3.4.3. Opportunities

CHAPTER 4: VACCINES MARKET, BY TECHNOLOGY TYPE

  • 4.1. Overview
    • 4.1.1. Market size and forecast
  • 4.2. Recombinant and Conjugate Vaccines
    • 4.2.1. Key market trends, growth factors and opportunities
    • 4.2.2. Market size and forecast, by region
    • 4.2.3. Market share analysis by country
  • 4.3. Live Attenuated Vaccines
    • 4.3.1. Key market trends, growth factors and opportunities
    • 4.3.2. Market size and forecast, by region
    • 4.3.3. Market share analysis by country
  • 4.4. Inactivated Vaccines
    • 4.4.1. Key market trends, growth factors and opportunities
    • 4.4.2. Market size and forecast, by region
    • 4.4.3. Market share analysis by country
  • 4.5. Toxoid Vaccines
    • 4.5.1. Key market trends, growth factors and opportunities
    • 4.5.2. Market size and forecast, by region
    • 4.5.3. Market share analysis by country
  • 4.6. Others
    • 4.6.1. Key market trends, growth factors and opportunities
    • 4.6.2. Market size and forecast, by region
    • 4.6.3. Market share analysis by country

CHAPTER 5: VACCINES MARKET, BY INDICATION

  • 5.1. Overview
    • 5.1.1. Market size and forecast
  • 5.2. Pneumococcal Disease
    • 5.2.1. Key market trends, growth factors and opportunities
    • 5.2.2. Market size and forecast, by region
    • 5.2.3. Market share analysis by country
  • 5.3. Influenza
    • 5.3.1. Key market trends, growth factors and opportunities
    • 5.3.2. Market size and forecast, by region
    • 5.3.3. Market share analysis by country
  • 5.4. Human Papilloma Virus
    • 5.4.1. Key market trends, growth factors and opportunities
    • 5.4.2. Market size and forecast, by region
    • 5.4.3. Market share analysis by country
  • 5.5. Meningococcal Disease
    • 5.5.1. Key market trends, growth factors and opportunities
    • 5.5.2. Market size and forecast, by region
    • 5.5.3. Market share analysis by country
  • 5.6. Rotavirus
    • 5.6.1. Key market trends, growth factors and opportunities
    • 5.6.2. Market size and forecast, by region
    • 5.6.3. Market share analysis by country
  • 5.7. Varicella
    • 5.7.1. Key market trends, growth factors and opportunities
    • 5.7.2. Market size and forecast, by region
    • 5.7.3. Market share analysis by country
  • 5.8. Measles, Mumps, and Rubella
    • 5.8.1. Key market trends, growth factors and opportunities
    • 5.8.2. Market size and forecast, by region
    • 5.8.3. Market share analysis by country
  • 5.9. Diphtheria, Pertussis, and Tetanus (DTP)
    • 5.9.1. Key market trends, growth factors and opportunities
    • 5.9.2. Market size and forecast, by region
    • 5.9.3. Market share analysis by country
  • 5.10. Polio
    • 5.10.1. Key market trends, growth factors and opportunities
    • 5.10.2. Market size and forecast, by region
    • 5.10.3. Market share analysis by country
  • 5.11. Hepatitis
    • 5.11.1. Key market trends, growth factors and opportunities
    • 5.11.2. Market size and forecast, by region
    • 5.11.3. Market share analysis by country
  • 5.12. Other Indications
    • 5.12.1. Key market trends, growth factors and opportunities
    • 5.12.2. Market size and forecast, by region
    • 5.12.3. Market share analysis by country

CHAPTER 6: VACCINES MARKET, BY END USER

  • 6.1. Overview
    • 6.1.1. Market size and forecast
  • 6.2. Pediatric
    • 6.2.1. Key market trends, growth factors and opportunities
    • 6.2.2. Market size and forecast, by region
    • 6.2.3. Market share analysis by country
  • 6.3. Adults
    • 6.3.1. Key market trends, growth factors and opportunities
    • 6.3.2. Market size and forecast, by region
    • 6.3.3. Market share analysis by country
  • 6.4. Travelers
    • 6.4.1. Key market trends, growth factors and opportunities
    • 6.4.2. Market size and forecast, by region
    • 6.4.3. Market share analysis by country

CHAPTER 7: VACCINES MARKET, BY REGION

  • 7.1. Overview
    • 7.1.1. Market size and forecast By Region
  • 7.2. North America
    • 7.2.1. Key market trends, growth factors and opportunities
    • 7.2.2. Market size and forecast, by Technology Type
    • 7.2.3. Market size and forecast, by Indication
    • 7.2.4. Market size and forecast, by End User
    • 7.2.5. Market size and forecast, by country
      • 7.2.5.1. U.S.
      • 7.2.5.1.1. Market size and forecast, by Technology Type
      • 7.2.5.1.2. Market size and forecast, by Indication
      • 7.2.5.1.3. Market size and forecast, by End User
      • 7.2.5.2. Canada
      • 7.2.5.2.1. Market size and forecast, by Technology Type
      • 7.2.5.2.2. Market size and forecast, by Indication
      • 7.2.5.2.3. Market size and forecast, by End User
      • 7.2.5.3. Mexico
      • 7.2.5.3.1. Market size and forecast, by Technology Type
      • 7.2.5.3.2. Market size and forecast, by Indication
      • 7.2.5.3.3. Market size and forecast, by End User
  • 7.3. Europe
    • 7.3.1. Key market trends, growth factors and opportunities
    • 7.3.2. Market size and forecast, by Technology Type
    • 7.3.3. Market size and forecast, by Indication
    • 7.3.4. Market size and forecast, by End User
    • 7.3.5. Market size and forecast, by country
      • 7.3.5.1. Germany
      • 7.3.5.1.1. Market size and forecast, by Technology Type
      • 7.3.5.1.2. Market size and forecast, by Indication
      • 7.3.5.1.3. Market size and forecast, by End User
      • 7.3.5.2. France
      • 7.3.5.3.2. Market size and forecast, by Indication
      • 7.3.5.3.3. Market size and forecast, by End User
      • 7.3.5.4. Italy
      • 7.3.5.4.1. Market size and forecast, by Technology Type
      • 7.3.5.4.2. Market size and forecast, by Indication
      • 7.3.5.4.3. Market size and forecast, by End User
      • 7.3.5.5. Spain
      • 7.3.5.5.1. Market size and forecast, by Technology Type
      • 7.3.5.5.2. Market size and forecast, by Indication
      • 7.3.5.5.3. Market size and forecast, by End User
      • 7.3.5.6. Rest of Europe
      • 7.3.5.6.1. Market size and forecast, by Technology Type
      • 7.3.5.6.2. Market size and forecast, by Indication
      • 7.3.5.6.3. Market size and forecast, by End User
  • 7.4. Asia-Pacific
    • 7.4.1. Key market trends, growth factors and opportunities
    • 7.4.2. Market size and forecast, by Technology Type
    • 7.4.3. Market size and forecast, by Indication
    • 7.4.4. Market size and forecast, by End User
    • 7.4.5. Market size and forecast, by country
      • 7.4.5.1. Japan
      • 7.4.5.1.1. Market size and forecast, by Technology Type
      • 7.4.5.1.2. Market size and forecast, by Indication
      • 7.4.5.1.3. Market size and forecast, by End User
      • 7.4.5.2. China
      • 7.4.5.2.1. Market size and forecast, by Technology Type
      • 7.4.5.2.2. Market size and forecast, by Indication
      • 7.4.5.2.3. Market size and forecast, by End User
      • 7.4.5.3. India
      • 7.4.5.3.1. Market size and forecast, by Technology Type
      • 7.4.5.3.2. Market size and forecast, by Indication
      • 7.4.5.3.3. Market size and forecast, by End User
      • 7.4.5.4. Australia
      • 7.4.5.4.1. Market size and forecast, by Technology Type
      • 7.4.5.4.2. Market size and forecast, by Indication
      • 7.4.5.4.3. Market size and forecast, by End User
      • 7.4.5.5. South Korea
      • 7.4.5.5.1. Market size and forecast, by Technology Type
      • 7.4.5.5.2. Market size and forecast, by Indication
      • 7.4.5.5.3. Market size and forecast, by End User
      • 7.4.5.6. Rest of Asia-Pacific
      • 7.4.5.6.1. Market size and forecast, by Technology Type
      • 7.4.5.6.2. Market size and forecast, by Indication
      • 7.4.5.6.3. Market size and forecast, by End User
  • 7.5. LAMEA
    • 7.5.1. Key market trends, growth factors and opportunities
    • 7.5.2. Market size and forecast, by Technology Type
    • 7.5.3. Market size and forecast, by Indication
    • 7.5.4. Market size and forecast, by End User
    • 7.5.5. Market size and forecast, by country
      • 7.5.5.1. Brazil
      • 7.5.5.1.1. Market size and forecast, by Technology Type
      • 7.5.5.1.2. Market size and forecast, by Indication
      • 7.5.5.1.3. Market size and forecast, by End User
      • 7.5.5.2. Saudi Arabia
      • 7.5.5.2.1. Market size and forecast, by Technology Type
      • 7.5.5.2.2. Market size and forecast, by Indication
      • 7.5.5.2.3. Market size and forecast, by End User
      • 7.5.5.3. South Africa
      • 7.5.5.3.1. Market size and forecast, by Technology Type
      • 7.5.5.3.2. Market size and forecast, by Indication
      • 7.5.5.3.3. Market size and forecast, by End User
      • 7.5.5.4. Rest of LAMEA
      • 7.5.5.4.1. Market size and forecast, by Technology Type
      • 7.5.5.4.2. Market size and forecast, by Indication
      • 7.5.5.4.3. Market size and forecast, by End User

CHAPTER 8: COMPETITIVE LANDSCAPE

  • 8.1. Introduction
  • 8.2. Top winning strategies
  • 8.3. Product mapping of top 10 player
  • 8.4. Competitive dashboard
  • 8.5. Competitive heatmap
  • 8.6. Top player positioning, 2023

CHAPTER 9: COMPANY PROFILES

  • 9.1. CSL Limited
    • 9.1.1. Company overview
    • 9.1.2. Key executives
    • 9.1.3. Company snapshot
    • 9.1.4. Operating business segments
    • 9.1.5. Product portfolio
    • 9.1.6. Business performance
    • 9.1.7. Key strategic moves and developments
  • 9.2. Emergent Bio Solutions Inc.
    • 9.2.1. Company overview
    • 9.2.2. Key executives
    • 9.2.3. Company snapshot
    • 9.2.4. Operating business segments
    • 9.2.5. Product portfolio
    • 9.2.6. Business performance
    • 9.2.7. Key strategic moves and developments
  • 9.3. GlaxoSmithKline Plc.
    • 9.3.1. Company overview
    • 9.3.2. Key executives
    • 9.3.3. Company snapshot
    • 9.3.4. Operating business segments
    • 9.3.5. Product portfolio
    • 9.3.6. Business performance
    • 9.3.7. Key strategic moves and developments
  • 9.4. Merck & Co., Inc.
    • 9.4.1. Company overview
    • 9.4.2. Key executives
    • 9.4.3. Company snapshot
    • 9.4.4. Operating business segments
    • 9.4.5. Product portfolio
    • 9.4.6. Business performance
    • 9.4.7. Key strategic moves and developments
  • 9.5. Pfizer
    • 9.5.1. Company overview
    • 9.5.2. Key executives
    • 9.5.3. Company snapshot
    • 9.5.4. Operating business segments
    • 9.5.5. Product portfolio
    • 9.5.6. Business performance
    • 9.5.7. Key strategic moves and developments
  • 9.6. Sanofi
    • 9.6.1. Company overview
    • 9.6.2. Key executives
    • 9.6.3. Company snapshot
    • 9.6.4. Operating business segments
    • 9.6.5. Product portfolio
    • 9.6.6. Business performance
    • 9.6.7. Key strategic moves and developments
  • 9.7. Serum Institute of India Pvt. Ltd.
    • 9.7.1. Company overview
    • 9.7.2. Key executives
    • 9.7.3. Company snapshot
    • 9.7.4. Operating business segments
    • 9.7.5. Product portfolio
    • 9.7.6. Business performance
    • 9.7.7. Key strategic moves and developments
  • 9.8. Bavarian Nordic
    • 9.8.1. Company overview
    • 9.8.2. Key executives
    • 9.8.3. Company snapshot
    • 9.8.4. Operating business segments
    • 9.8.5. Product portfolio
    • 9.8.6. Business performance
    • 9.8.7. Key strategic moves and developments
  • 9.9. Zhi Fei Biological
    • 9.9.1. Company overview
    • 9.9.2. Key executives
    • 9.9.3. Company snapshot
    • 9.9.4. Operating business segments
    • 9.9.5. Product portfolio
    • 9.9.6. Business performance
    • 9.9.7. Key strategic moves and developments
  • 9.10. Bharat Biotech
    • 9.10.1. Company overview
    • 9.10.2. Key executives
    • 9.10.3. Company snapshot
    • 9.10.4. Operating business segments
    • 9.10.5. Product portfolio
    • 9.10.6. Business performance
    • 9.10.7. Key strategic moves and developments

LIST OF TABLES

  • TABLE 01. GLOBAL VACCINES MARKET, BY TECHNOLOGY TYPE, 2023-2035 ($MILLION)
  • TABLE 02. VACCINES MARKET FOR RECOMBINANT AND CONJUGATE VACCINES, BY REGION, 2023-2035 ($MILLION)
  • TABLE 03. VACCINES MARKET FOR LIVE ATTENUATED VACCINES, BY REGION, 2023-2035 ($MILLION)
  • TABLE 04. VACCINES MARKET FOR INACTIVATED VACCINES, BY REGION, 2023-2035 ($MILLION)
  • TABLE 05. VACCINES MARKET FOR TOXOID VACCINES, BY REGION, 2023-2035 ($MILLION)
  • TABLE 06. VACCINES MARKET FOR OTHERS, BY REGION, 2023-2035 ($MILLION)
  • TABLE 07. GLOBAL VACCINES MARKET, BY INDICATION, 2023-2035 ($MILLION)
  • TABLE 08. VACCINES MARKET FOR PNEUMOCOCCAL DISEASE, BY REGION, 2023-2035 ($MILLION)
  • TABLE 09. VACCINES MARKET FOR INFLUENZA, BY REGION, 2023-2035 ($MILLION)
  • TABLE 10. VACCINES MARKET FOR HUMAN PAPILLOMA VIRUS, BY REGION, 2023-2035 ($MILLION)
  • TABLE 11. VACCINES MARKET FOR MENINGOCOCCAL DISEASE, BY REGION, 2023-2035 ($MILLION)
  • TABLE 12. VACCINES MARKET FOR ROTAVIRUS, BY REGION, 2023-2035 ($MILLION)
  • TABLE 13. VACCINES MARKET FOR VARICELLA, BY REGION, 2023-2035 ($MILLION)
  • TABLE 14. VACCINES MARKET FOR MEASLES, MUMPS, AND RUBELLA, BY REGION, 2023-2035 ($MILLION)
  • TABLE 15. VACCINES MARKET FOR DIPHTHERIA, PERTUSSIS, AND TETANUS (DTP), BY REGION, 2023-2035 ($MILLION)
  • TABLE 16. VACCINES MARKET FOR POLIO, BY REGION, 2023-2035 ($MILLION)
  • TABLE 17. VACCINES MARKET FOR HEPATITIS, BY REGION, 2023-2035 ($MILLION)
  • TABLE 18. VACCINES MARKET FOR OTHER INDICATIONS, BY REGION, 2023-2035 ($MILLION)
  • TABLE 19. GLOBAL VACCINES MARKET, BY END USER, 2023-2035 ($MILLION)
  • TABLE 20. VACCINES MARKET FOR PEDIATRIC, BY REGION, 2023-2035 ($MILLION)
  • TABLE 21. VACCINES MARKET FOR ADULTS, BY REGION, 2023-2035 ($MILLION)
  • TABLE 22. VACCINES MARKET FOR TRAVELERS, BY REGION, 2023-2035 ($MILLION)
  • TABLE 23. VACCINES MARKET, BY REGION, 2023-2035 ($MILLION)
  • TABLE 24. NORTH AMERICA VACCINES MARKET, BY TECHNOLOGY TYPE, 2023-2035 ($MILLION)
  • TABLE 25. NORTH AMERICA VACCINES MARKET, BY INDICATION, 2023-2035 ($MILLION)
  • TABLE 26. NORTH AMERICA VACCINES MARKET, BY END USER, 2023-2035 ($MILLION)
  • TABLE 27. NORTH AMERICA VACCINES MARKET, BY COUNTRY, 2023-2035 ($MILLION)
  • TABLE 28. U.S. VACCINES MARKET, BY TECHNOLOGY TYPE, 2023-2035 ($MILLION)
  • TABLE 29. U.S. VACCINES MARKET, BY INDICATION, 2023-2035 ($MILLION)
  • TABLE 30. U.S. VACCINES MARKET, BY END USER, 2023-2035 ($MILLION)
  • TABLE 31. CANADA VACCINES MARKET, BY TECHNOLOGY TYPE, 2023-2035 ($MILLION)
  • TABLE 32. CANADA VACCINES MARKET, BY INDICATION, 2023-2035 ($MILLION)
  • TABLE 33. CANADA VACCINES MARKET, BY END USER, 2023-2035 ($MILLION)
  • TABLE 34. MEXICO VACCINES MARKET, BY TECHNOLOGY TYPE, 2023-2035 ($MILLION)
  • TABLE 35. MEXICO VACCINES MARKET, BY INDICATION, 2023-2035 ($MILLION)
  • TABLE 36. MEXICO VACCINES MARKET, BY END USER, 2023-2035 ($MILLION)
  • TABLE 37. EUROPE VACCINES MARKET, BY TECHNOLOGY TYPE, 2023-2035 ($MILLION)
  • TABLE 38. EUROPE VACCINES MARKET, BY INDICATION, 2023-2035 ($MILLION)
  • TABLE 39. EUROPE VACCINES MARKET, BY END USER, 2023-2035 ($MILLION)
  • TABLE 40. EUROPE VACCINES MARKET, BY COUNTRY, 2023-2035 ($MILLION)
  • TABLE 41. GERMANY VACCINES MARKET, BY TECHNOLOGY TYPE, 2023-2035 ($MILLION)
  • TABLE 42. GERMANY VACCINES MARKET, BY INDICATION, 2023-2035 ($MILLION)
  • TABLE 43. GERMANY VACCINES MARKET, BY END USER, 2023-2035 ($MILLION)
  • TABLE 44. FRANCE VACCINES MARKET, BY TECHNOLOGY TYPE, 2023-2035 ($MILLION)
  • TABLE 45. FRANCE VACCINES MARKET, BY INDICATION, 2023-2035 ($MILLION)
  • TABLE 46. FRANCE VACCINES MARKET, BY END USER, 2023-2035 ($MILLION)
  • TABLE 47. UK VACCINES MARKET, BY TECHNOLOGY TYPE, 2023-2035 ($MILLION)
  • TABLE 48. UK VACCINES MARKET, BY INDICATION, 2023-2035 ($MILLION)
  • TABLE 49. UK VACCINES MARKET, BY END USER, 2023-2035 ($MILLION)
  • TABLE 50. ITALY VACCINES MARKET, BY TECHNOLOGY TYPE, 2023-2035 ($MILLION)
  • TABLE 51. ITALY VACCINES MARKET, BY INDICATION, 2023-2035 ($MILLION)
  • TABLE 52. ITALY VACCINES MARKET, BY END USER, 2023-2035 ($MILLION)
  • TABLE 53. SPAIN VACCINES MARKET, BY TECHNOLOGY TYPE, 2023-2035 ($MILLION)
  • TABLE 54. SPAIN VACCINES MARKET, BY INDICATION, 2023-2035 ($MILLION)
  • TABLE 55. SPAIN VACCINES MARKET, BY END USER, 2023-2035 ($MILLION)
  • TABLE 56. REST OF EUROPE VACCINES MARKET, BY TECHNOLOGY TYPE, 2023-2035 ($MILLION)
  • TABLE 57. REST OF EUROPE VACCINES MARKET, BY INDICATION, 2023-2035 ($MILLION)
  • TABLE 58. REST OF EUROPE VACCINES MARKET, BY END USER, 2023-2035 ($MILLION)
  • TABLE 59. ASIA-PACIFIC VACCINES MARKET, BY TECHNOLOGY TYPE, 2023-2035 ($MILLION)
  • TABLE 60. ASIA-PACIFIC VACCINES MARKET, BY INDICATION, 2023-2035 ($MILLION)
  • TABLE 61. ASIA-PACIFIC VACCINES MARKET, BY END USER, 2023-2035 ($MILLION)
  • TABLE 62. ASIA-PACIFIC VACCINES MARKET, BY COUNTRY, 2023-2035 ($MILLION)
  • TABLE 63. JAPAN VACCINES MARKET, BY TECHNOLOGY TYPE, 2023-2035 ($MILLION)
  • TABLE 64. JAPAN VACCINES MARKET, BY INDICATION, 2023-2035 ($MILLION)
  • TABLE 65. JAPAN VACCINES MARKET, BY END USER, 2023-2035 ($MILLION)
  • TABLE 66. CHINA VACCINES MARKET, BY TECHNOLOGY TYPE, 2023-2035 ($MILLION)
  • TABLE 67. CHINA VACCINES MARKET, BY INDICATION, 2023-2035 ($MILLION)
  • TABLE 68. CHINA VACCINES MARKET, BY END USER, 2023-2035 ($MILLION)
  • TABLE 69. INDIA VACCINES MARKET, BY TECHNOLOGY TYPE, 2023-2035 ($MILLION)
  • TABLE 70. INDIA VACCINES MARKET, BY INDICATION, 2023-2035 ($MILLION)
  • TABLE 71. INDIA VACCINES MARKET, BY END USER, 2023-2035 ($MILLION)
  • TABLE 72. AUSTRALIA VACCINES MARKET, BY TECHNOLOGY TYPE, 2023-2035 ($MILLION)
  • TABLE 73. AUSTRALIA VACCINES MARKET, BY INDICATION, 2023-2035 ($MILLION)
  • TABLE 74. AUSTRALIA VACCINES MARKET, BY END USER, 2023-2035 ($MILLION)
  • TABLE 75. SOUTH KOREA VACCINES MARKET, BY TECHNOLOGY TYPE, 2023-2035 ($MILLION)
  • TABLE 76. SOUTH KOREA VACCINES MARKET, BY INDICATION, 2023-2035 ($MILLION)
  • TABLE 77. SOUTH KOREA VACCINES MARKET, BY END USER, 2023-2035 ($MILLION)
  • TABLE 78. REST OF ASIA-PACIFIC VACCINES MARKET, BY TECHNOLOGY TYPE, 2023-2035 ($MILLION)
  • TABLE 79. REST OF ASIA-PACIFIC VACCINES MARKET, BY INDICATION, 2023-2035 ($MILLION)
  • TABLE 80. REST OF ASIA-PACIFIC VACCINES MARKET, BY END USER, 2023-2035 ($MILLION)
  • TABLE 81. LAMEA VACCINES MARKET, BY TECHNOLOGY TYPE, 2023-2035 ($MILLION)
  • TABLE 82. LAMEA VACCINES MARKET, BY INDICATION, 2023-2035 ($MILLION)
  • TABLE 83. LAMEA VACCINES MARKET, BY END USER, 2023-2035 ($MILLION)
  • TABLE 84. LAMEA VACCINES MARKET, BY COUNTRY, 2023-2035 ($MILLION)
  • TABLE 85. BRAZIL VACCINES MARKET, BY TECHNOLOGY TYPE, 2023-2035 ($MILLION)
  • TABLE 86. BRAZIL VACCINES MARKET, BY INDICATION, 2023-2035 ($MILLION)
  • TABLE 87. BRAZIL VACCINES MARKET, BY END USER, 2023-2035 ($MILLION)
  • TABLE 88. SAUDI ARABIA VACCINES MARKET, BY TECHNOLOGY TYPE, 2023-2035 ($MILLION)
  • TABLE 89. SAUDI ARABIA VACCINES MARKET, BY INDICATION, 2023-2035 ($MILLION)
  • TABLE 90. SAUDI ARABIA VACCINES MARKET, BY END USER, 2023-2035 ($MILLION)
  • TABLE 91. SOUTH AFRICA VACCINES MARKET, BY TECHNOLOGY TYPE, 2023-2035 ($MILLION)
  • TABLE 92. SOUTH AFRICA VACCINES MARKET, BY INDICATION, 2023-2035 ($MILLION)
  • TABLE 93. SOUTH AFRICA VACCINES MARKET, BY END USER, 2023-2035 ($MILLION)
  • TABLE 94. REST OF LAMEA VACCINES MARKET, BY TECHNOLOGY TYPE, 2023-2035 ($MILLION)
  • TABLE 95. REST OF LAMEA VACCINES MARKET, BY INDICATION, 2023-2035 ($MILLION)
  • TABLE 96. REST OF LAMEA VACCINES MARKET, BY END USER, 2023-2035 ($MILLION)
  • TABLE 97. CSL LIMITED: KEY EXECUTIVES
  • TABLE 98. CSL LIMITED: COMPANY SNAPSHOT
  • TABLE 99. CSL LIMITED: PRODUCT SEGMENTS
  • TABLE 100. CSL LIMITED: SERVICE SEGMENTS
  • TABLE 101. CSL LIMITED: PRODUCT PORTFOLIO
  • TABLE 102. CSL LIMITED: KEY STRATEGIES
  • TABLE 103. EMERGENT BIO SOLUTIONS INC.: KEY EXECUTIVES
  • TABLE 104. EMERGENT BIO SOLUTIONS INC.: COMPANY SNAPSHOT
  • TABLE 105. EMERGENT BIO SOLUTIONS INC.: PRODUCT SEGMENTS
  • TABLE 106. EMERGENT BIO SOLUTIONS INC.: SERVICE SEGMENTS
  • TABLE 107. EMERGENT BIO SOLUTIONS INC.: PRODUCT PORTFOLIO
  • TABLE 108. EMERGENT BIO SOLUTIONS INC.: KEY STRATEGIES
  • TABLE 109. GLAXOSMITHKLINE PLC.: KEY EXECUTIVES
  • TABLE 110. GLAXOSMITHKLINE PLC.: COMPANY SNAPSHOT
  • TABLE 111. GLAXOSMITHKLINE PLC.: PRODUCT SEGMENTS
  • TABLE 112. GLAXOSMITHKLINE PLC.: SERVICE SEGMENTS
  • TABLE 113. GLAXOSMITHKLINE PLC.: PRODUCT PORTFOLIO
  • TABLE 114. GLAXOSMITHKLINE PLC.: KEY STRATEGIES
  • TABLE 115. MERCK & CO., INC.: KEY EXECUTIVES
  • TABLE 116. MERCK & CO., INC.: COMPANY SNAPSHOT
  • TABLE 117. MERCK & CO., INC.: PRODUCT SEGMENTS
  • TABLE 118. MERCK & CO., INC.: SERVICE SEGMENTS
  • TABLE 119. MERCK & CO., INC.: PRODUCT PORTFOLIO
  • TABLE 120. MERCK & CO., INC.: KEY STRATEGIES
  • TABLE 121. PFIZER: KEY EXECUTIVES
  • TABLE 122. PFIZER: COMPANY SNAPSHOT
  • TABLE 123. PFIZER: PRODUCT SEGMENTS
  • TABLE 124. PFIZER: SERVICE SEGMENTS
  • TABLE 125. PFIZER: PRODUCT PORTFOLIO
  • TABLE 126. PFIZER: KEY STRATEGIES
  • TABLE 127. SANOFI: KEY EXECUTIVES
  • TABLE 128. SANOFI: COMPANY SNAPSHOT
  • TABLE 129. SANOFI: PRODUCT SEGMENTS
  • TABLE 130. SANOFI: SERVICE SEGMENTS
  • TABLE 131. SANOFI: PRODUCT PORTFOLIO
  • TABLE 132. SANOFI: KEY STRATEGIES
  • TABLE 133. SERUM INSTITUTE OF INDIA PVT. LTD.: KEY EXECUTIVES
  • TABLE 134. SERUM INSTITUTE OF INDIA PVT. LTD.: COMPANY SNAPSHOT
  • TABLE 135. SERUM INSTITUTE OF INDIA PVT. LTD.: PRODUCT SEGMENTS
  • TABLE 136. SERUM INSTITUTE OF INDIA PVT. LTD.: SERVICE SEGMENTS
  • TABLE 137. SERUM INSTITUTE OF INDIA PVT. LTD.: PRODUCT PORTFOLIO
  • TABLE 138. SERUM INSTITUTE OF INDIA PVT. LTD.: KEY STRATEGIES
  • TABLE 139. BAVARIAN NORDIC: KEY EXECUTIVES
  • TABLE 140. BAVARIAN NORDIC: COMPANY SNAPSHOT
  • TABLE 141. BAVARIAN NORDIC: PRODUCT SEGMENTS
  • TABLE 142. BAVARIAN NORDIC: SERVICE SEGMENTS
  • TABLE 143. BAVARIAN NORDIC: PRODUCT PORTFOLIO
  • TABLE 144. BAVARIAN NORDIC: KEY STRATEGIES
  • TABLE 145. ZHI FEI BIOLOGICAL: KEY EXECUTIVES
  • TABLE 146. ZHI FEI BIOLOGICAL: COMPANY SNAPSHOT
  • TABLE 147. ZHI FEI BIOLOGICAL: PRODUCT SEGMENTS
  • TABLE 148. ZHI FEI BIOLOGICAL: SERVICE SEGMENTS
  • TABLE 149. ZHI FEI BIOLOGICAL: PRODUCT PORTFOLIO
  • TABLE 150. ZHI FEI BIOLOGICAL: KEY STRATEGIES
  • TABLE 151. BHARAT BIOTECH: KEY EXECUTIVES
  • TABLE 152. BHARAT BIOTECH: COMPANY SNAPSHOT
  • TABLE 153. BHARAT BIOTECH: PRODUCT SEGMENTS
  • TABLE 154. BHARAT BIOTECH: SERVICE SEGMENTS
  • TABLE 155. BHARAT BIOTECH: PRODUCT PORTFOLIO
  • TABLE 156. BHARAT BIOTECH: KEY STRATEGIES

LIST OF FIGURES

  • FIGURE 01. VACCINES MARKET, 2023-2035
  • FIGURE 02. SEGMENTATION OF VACCINES MARKET,2023-2035
  • FIGURE 03. TOP IMPACTING FACTORS IN VACCINES MARKET
  • FIGURE 04. TOP INVESTMENT POCKETS IN VACCINES MARKET (2024-2035)
  • FIGURE 05. BARGAINING POWER OF SUPPLIERS
  • FIGURE 06. BARGAINING POWER OF BUYERS
  • FIGURE 07. THREAT OF SUBSTITUTION
  • FIGURE 08. THREAT OF SUBSTITUTION
  • FIGURE 09. COMPETITIVE RIVALRY
  • FIGURE 10. GLOBAL VACCINES MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
  • FIGURE 11. VACCINES MARKET, BY TECHNOLOGY TYPE, 2023 AND 2035(%)
  • FIGURE 12. COMPARATIVE SHARE ANALYSIS OF VACCINES MARKET FOR RECOMBINANT AND CONJUGATE VACCINES, BY COUNTRY 2023 AND 2035(%)
  • FIGURE 13. COMPARATIVE SHARE ANALYSIS OF VACCINES MARKET FOR LIVE ATTENUATED VACCINES, BY COUNTRY 2023 AND 2035(%)
  • FIGURE 14. COMPARATIVE SHARE ANALYSIS OF VACCINES MARKET FOR INACTIVATED VACCINES, BY COUNTRY 2023 AND 2035(%)
  • FIGURE 15. COMPARATIVE SHARE ANALYSIS OF VACCINES MARKET FOR TOXOID VACCINES, BY COUNTRY 2023 AND 2035(%)
  • FIGURE 16. COMPARATIVE SHARE ANALYSIS OF VACCINES MARKET FOR OTHERS, BY COUNTRY 2023 AND 2035(%)
  • FIGURE 17. VACCINES MARKET, BY INDICATION, 2023 AND 2035(%)
  • FIGURE 18. COMPARATIVE SHARE ANALYSIS OF VACCINES MARKET FOR PNEUMOCOCCAL DISEASE, BY COUNTRY 2023 AND 2035(%)
  • FIGURE 19. COMPARATIVE SHARE ANALYSIS OF VACCINES MARKET FOR INFLUENZA, BY COUNTRY 2023 AND 2035(%)
  • FIGURE 20. COMPARATIVE SHARE ANALYSIS OF VACCINES MARKET FOR HUMAN PAPILLOMA VIRUS, BY COUNTRY 2023 AND 2035(%)
  • FIGURE 21. COMPARATIVE SHARE ANALYSIS OF VACCINES MARKET FOR MENINGOCOCCAL DISEASE, BY COUNTRY 2023 AND 2035(%)
  • FIGURE 22. COMPARATIVE SHARE ANALYSIS OF VACCINES MARKET FOR ROTAVIRUS, BY COUNTRY 2023 AND 2035(%)
  • FIGURE 23. COMPARATIVE SHARE ANALYSIS OF VACCINES MARKET FOR VARICELLA, BY COUNTRY 2023 AND 2035(%)
  • FIGURE 24. COMPARATIVE SHARE ANALYSIS OF VACCINES MARKET FOR MEASLES, MUMPS, AND RUBELLA, BY COUNTRY 2023 AND 2035(%)
  • FIGURE 25. COMPARATIVE SHARE ANALYSIS OF VACCINES MARKET FOR DIPHTHERIA, PERTUSSIS, AND TETANUS (DTP), BY COUNTRY 2023 AND 2035(%)
  • FIGURE 26. COMPARATIVE SHARE ANALYSIS OF VACCINES MARKET FOR POLIO, BY COUNTRY 2023 AND 2035(%)
  • FIGURE 27. COMPARATIVE SHARE ANALYSIS OF VACCINES MARKET FOR HEPATITIS, BY COUNTRY 2023 AND 2035(%)
  • FIGURE 28. COMPARATIVE SHARE ANALYSIS OF VACCINES MARKET FOR OTHER INDICATIONS, BY COUNTRY 2023 AND 2035(%)
  • FIGURE 29. VACCINES MARKET, BY END USER, 2023 AND 2035(%)
  • FIGURE 30. COMPARATIVE SHARE ANALYSIS OF VACCINES MARKET FOR PEDIATRIC, BY COUNTRY 2023 AND 2035(%)
  • FIGURE 31. COMPARATIVE SHARE ANALYSIS OF VACCINES MARKET FOR ADULTS, BY COUNTRY 2023 AND 2035(%)
  • FIGURE 32. COMPARATIVE SHARE ANALYSIS OF VACCINES MARKET FOR TRAVELERS, BY COUNTRY 2023 AND 2035(%)
  • FIGURE 33. VACCINES MARKET BY REGION, 2023 AND 2035(%)
  • FIGURE 34. U.S. VACCINES MARKET, 2023-2035 ($MILLION)
  • FIGURE 35. CANADA VACCINES MARKET, 2023-2035 ($MILLION)
  • FIGURE 36. MEXICO VACCINES MARKET, 2023-2035 ($MILLION)
  • FIGURE 37. GERMANY VACCINES MARKET, 2023-2035 ($MILLION)
  • FIGURE 38. FRANCE VACCINES MARKET, 2023-2035 ($MILLION)
  • FIGURE 39. UK VACCINES MARKET, 2023-2035 ($MILLION)
  • FIGURE 40. ITALY VACCINES MARKET, 2023-2035 ($MILLION)
  • FIGURE 41. SPAIN VACCINES MARKET, 2023-2035 ($MILLION)
  • FIGURE 42. REST OF EUROPE VACCINES MARKET, 2023-2035 ($MILLION)
  • FIGURE 43. JAPAN VACCINES MARKET, 2023-2035 ($MILLION)
  • FIGURE 44. CHINA VACCINES MARKET, 2023-2035 ($MILLION)
  • FIGURE 45. INDIA VACCINES MARKET, 2023-2035 ($MILLION)
  • FIGURE 46. AUSTRALIA VACCINES MARKET, 2023-2035 ($MILLION)
  • FIGURE 47. SOUTH KOREA VACCINES MARKET, 2023-2035 ($MILLION)
  • FIGURE 48. REST OF ASIA-PACIFIC VACCINES MARKET, 2023-2035 ($MILLION)
  • FIGURE 49. BRAZIL VACCINES MARKET, 2023-2035 ($MILLION)
  • FIGURE 50. SAUDI ARABIA VACCINES MARKET, 2023-2035 ($MILLION)
  • FIGURE 51. SOUTH AFRICA VACCINES MARKET, 2023-2035 ($MILLION)
  • FIGURE 52. REST OF LAMEA VACCINES MARKET, 2023-2035 ($MILLION)
  • FIGURE 53. TOP WINNING STRATEGIES, BY YEAR
  • FIGURE 54. TOP WINNING STRATEGIES, BY DEVELOPMENT
  • FIGURE 55. TOP WINNING STRATEGIES, BY COMPANY
  • FIGURE 56. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 57. COMPETITIVE DASHBOARD
  • FIGURE 58. COMPETITIVE HEATMAP: VACCINES MARKET
  • FIGURE 59. TOP PLAYER POSITIONING, 2023